Inspire Medical Systems
INSP
67.45
-0.75
-1.10%
Inspire Medical Systems
US · INSP
#2781 by market cap
Listed 2018
67.45
-0.75
-1.10%
Live - 5344 symbols - heartbeat 465s ago
· 2026-10-07 19:54
After-hours
67.45
0.00%
- Market cap
- 1.95B
- P/E (TTM)i
- 14.89
- P/Bi
- 2.36
- EPSi
- 4.89
- Div yieldi
- 0.00%
- 52W posi
- 26%
Reader sentiment
Are you bullish or bearish on INSP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.88, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +13.60% YoY
Margins
- Gross margin
- 85.39%
- Operating margin
- 5.59%
- Net margin
- 15.95%
Key ratios & quality
- Altman Z-Scorei
- 10.88
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.59M | 82.05M | 115.38M | 233.39M | 407.86M | 624.80M | 802.80M | 911.98M |
| Gross profit | 40.54M | 68.41M | 97.76M | 200.12M | 341.74M | 528.22M | 679.82M | 778.76M |
| Selling & admin expenses | 53.53M | 90.47M | 127.87M | 202.62M | 320.69M | 451.96M | 529.61M | 624.64M |
| Research & development | 7.39M | 12.84M | 26.09M | 37.35M | 68.65M | 116.54M | 114.13M | 103.17M |
| Operating profit | -20.38M | -34.90M | -56.21M | -39.85M | -47.59M | -40.27M | 36.08M | 50.95M |
| Pretax profit | -21.83M | -33.20M | -57.09M | -41.97M | -44.27M | -19.91M | 58.45M | 65.70M |
| Tax | 0 | 40.00K | 115.00K | 72.00K | 613.00K | 1.25M | 4.94M | -79.73M |
| Net profit | -21.83M | -33.24M | -57.20M | -42.04M | -44.88M | -21.15M | 53.51M | 145.42M |
| Basic EPS | -2 | -1 | -2 | -2 | -2 | -1 | 2 | 5 |
| Diluted EPS | -1.50 | -1.40 | -2.19 | -1.54 | -1.60 | -0.72 | 1.75 | 4.89 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 201.32M | 217.09M | 224.50M | 269.08M | 204.58M | 200.58M |
| Gross profit | 170.61M | 182.41M | 192.73M | 233.01M | 176.91M | 171.46M |
| Selling & admin expenses | 144.29M | 159.52M | 158.87M | 161.95M | 152.20M | 147.28M |
| Research & development | 27.80M | 26.21M | 24.21M | 24.94M | 25.83M | 24.70M |
| Operating profit | -1.49M | -3.32M | 9.64M | 46.11M | -1.12M | -514.00K |
| Pretax profit | 4.16M | -2.33M | 13.55M | 50.32M | 2.40M | 3.12M |
| Tax | 1.17M | 1.26M | 3.62M | -85.77M | 13.69M | 2.80M |
| Net profit | 2.99M | -3.59M | 9.93M | 136.09M | -11.29M | 314.00K |
| Basic EPS | 0 | 0 | 0 | 5 | 0 | 0 |
| Diluted EPS | 0.10 | -0.12 | 0.34 | 4.66 | -0.39 | 0.01 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 199.28M | 170.64M | 269.87M | 268.54M | 530.03M | 593.74M | 630.81M | 583.65M |
| Cash & ST investments | 188.21M | 149.47M | 234.36M | 214.47M | 451.41M | 460.38M | 445.55M | 308.27M |
| Inventory | 2.67M | 5.83M | 8.48M | 17.23M | 11.89M | 33.89M | 80.12M | 145.29M |
| Total assets | 200.08M | 181.25M | 281.19M | 295.08M | 564.88M | 676.81M | 808.38M | 907.32M |
| Total current liabilities | 11.16M | 16.86M | 20.73M | 41.31M | 61.19M | 78.11M | 88.50M | 96.06M |
| Short-term debt | -- | 828.00K | -- | 9.50M | 1.34M | -- | 1.75M | 2.16M |
| Long-term debt | 24.93M | 24.52M | 24.75M | 15.80M | -- | -- | -- | -- |
| Total liabilities | 36,081,000.00 | 41,418,000.00 | 51,442,000.00 | 66,036,000.00 | 68,868,000.00 | 104,297,000.00 | 118,688,000.00 | 126,157,000.00 |
| Total equity | 164.00M | 139.84M | 229.75M | 229.05M | 496.01M | 572.51M | 689.70M | 781.16M |
| Retained earnings | -146.91M | -180.16M | -237.35M | -279.39M | -324.27M | -345.42M | -291.91M | -146.49M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 571.68M | 573.19M | 586.49M | 583.65M | 566.82M | 608.67M |
| Cash & ST investments | 369.19M | 300.90M | 322.59M | 308.27M | 283.83M | 320.68M |
| Inventory | 99.73M | 121.63M | 141.78M | 145.29M | 166.24M | 170.45M |
| Total assets | 730.81M | 802.19M | 807.72M | 907.32M | 911.38M | 925.99M |
| Total current liabilities | 63.47M | 93.36M | 110.84M | 96.06M | 89.42M | 71.18M |
| Short-term debt | 2.04M | 2.15M | 2.27M | 2.16M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 95,066,000.00 | 124,379,000.00 | 141,256,000.00 | 126,157,000.00 | 119,036,000.00 | 100,411,000.00 |
| Total equity | 635.74M | 677.81M | 666.46M | 781.16M | 792.34M | 825.58M |
| Retained earnings | -288.92M | -292.51M | -282.58M | -146.49M | -157.79M | -157.47M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -18.69M | -32.85M | -53.05M | -20.12M | 11.57M | 24.65M | 130.25M | 116.98M |
| Depreciation & amortization | 393.00K | 495.00K | 840.00K | 1.22M | 1.86M | 2.85M | 6.55M | 13.96M |
| Free cash flow | -18.94M | -35.59M | -55.50M | -24.79M | 2.47M | 1.02M | 91.12M | 78.48M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 181.83M | 0 | 124.65M | 0 | 243.80M | 0 | -75.00M | -175.02M |
| Ending cash balance | 97.29M | 22.86M | 190.52M | 214.47M | 441.59M | 185.54M | 150.15M | 104.81M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -6.70M | 2.68M | 68.53M | 52.47M | 12.85M | 23.23M |
| Depreciation & amortization | 3.04M | 3.41M | 3.68M | 3.82M | 5.11M | 4.60M |
| Free cash flow | -15.11M | -6.31M | 58.09M | 41.81M | 3.12M | 14.07M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -75.01M | 0 | -50.00M | -50.01M | 0 | 0 |
| Ending cash balance | 53.88M | 106.93M | 112.85M | 104.81M | 98.93M | 127.76M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -26.38 | -21.88 | -30.96 | -18.33 | -12.38 | -3.96 | 8.48 | 19.77 |
| ROA %i | -19.39 | -17.44 | -24.74 | -14.59 | -10.44 | -3.41 | 7.21 | 16.95 |
| ROIC %i | -19.72 | -19.51 | -26.58 | -15.23 | -12.38 | -6.79 | 4.88 | 17.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -35.60 | -17.50 | -11.43 | -1.28 |
| EBIT margin %i | -36.61 | -37.88 | -47.64 | -17.07 | -10.44 | -3.19 | 7.28 | 7.22 |
| FCF / sales %i | -- | -- | -- | -- | 0.61 | 0.16 | 11.35 | 8.61 |
| Current ratioi | 17.86 | 10.12 | 13.02 | 6.50 | 8.66 | 7.60 | 7.13 | 6.08 |
| Quick ratioi | 17.47 | 9.65 | 12.52 | 6.02 | 8.38 | 7.05 | 6.09 | 4.46 |
| Debt / assetsi | 12.46 | 13.99 | 10.89 | 11.55 | 1.57 | 3.67 | 3.93 | 3.54 |
| LT debt / equityi | 15.20 | 17.54 | 13.33 | 10.74 | 1.52 | 4.34 | 4.36 | 3.84 |
| Interest coveragei | -5.61 | -14.67 | -25.97 | -18.72 | -25.40 | -- | 2,657.95 | 480.54 |
| Revenue CAGR (3Y) %i | 84.83 | 70.94 | 59.25 | 66.47 | 70.66 | 75.60 | 50.95 | 30.77 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | 216.60 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 10.86 | 8.07 | 6.54 | 19.77 | 18.37 | 17.96 |
| ROA %i | 9.39 | 6.94 | 5.56 | 16.95 | 15.97 | 15.63 |
| ROIC %i | 7.13 | 4.97 | 3.97 | 17.16 | 16.31 | 16.09 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 8.60 | 6.83 | 5.90 | 7.22 | 7.23 | 7.68 |
| FCF / sales %i | 9.39 | 9.87 | 11.20 | 8.61 | 10.57 | 13.03 |
| Current ratioi | 9.01 | 6.14 | 5.29 | 6.08 | 6.34 | 8.55 |
| Quick ratioi | 7.28 | 4.70 | 3.88 | 4.46 | 4.35 | 5.96 |
| Debt / assetsi | 4.59 | 4.12 | 4.03 | 3.54 | 3.24 | 3.14 |
| LT debt / equityi | 4.95 | 4.56 | 4.55 | 3.84 | 3.73 | 3.52 |
| Interest coveragei | -- | 2,262.12 | 1,406.78 | 480.54 | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.